PL1976524T3 - Zastosowanie kombinacji morfiny i co najmniej jednego antagonisty opiatów do leczenia uzależnienia od opiatów i do zapobiegania niedoustnemu nadużywaniu opiatów przez uzależnionych od opiatów - Google Patents

Zastosowanie kombinacji morfiny i co najmniej jednego antagonisty opiatów do leczenia uzależnienia od opiatów i do zapobiegania niedoustnemu nadużywaniu opiatów przez uzależnionych od opiatów

Info

Publication number: PL1976524T3
Authority: PL; Poland
Prior art keywords: opiate; morphine; antagonist; prevention; treatment
Prior art date: 2006-01-19

Application number

PL07704010T

Other languages

English (en)

Other versions

PL1976524T5 (pl

Inventor

Lars Hermann

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-01-19

Filing date

2007-01-19

Publication date

2010-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36675685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1976524(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-19 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2010-10-29 Publication of PL1976524T3 publication Critical patent/PL1976524T3/pl

2017-12-29 Publication of PL1976524T5 publication Critical patent/PL1976524T5/pl

Links

BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title abstract 4
229940127240 opiate Drugs 0.000 title abstract 3
229960005181 morphine Drugs 0.000 title abstract 2
239000003401 opiate antagonist Substances 0.000 title abstract 2
208000026251 Opioid-Related disease Diseases 0.000 title 1
230000002265 prevention Effects 0.000 title 1
230000000694 effects Effects 0.000 abstract 2
230000008485 antagonism Effects 0.000 abstract 1
230000003111 delayed effect Effects 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL07704010T 2006-01-19 2007-01-19 Zastosowanie kombinacji morfiny i co najmniej jednego antagonisty opiatów do leczenia uzależnienia od opiatów i do zapobiegania niedoustnemu nadużywaniu opiatów przez uzależnionych od opiatów PL1976524T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06100578A EP1810678A1 (de)	2006-01-19	2006-01-19	Verwendung einer Kombination von Morphin und Naloxon zur Drogensubstitution
PCT/EP2007/050540 WO2007082935A1 (de)	2006-01-19	2007-01-19	Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
EP07704010.3A EP1976524B2 (de)	2006-01-19	2007-01-19	Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen

Publications (2)

Publication Number	Publication Date
PL1976524T3 true PL1976524T3 (pl)	2010-10-29
PL1976524T5 PL1976524T5 (pl)	2017-12-29

Family

ID=36675685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07704010T PL1976524T5 (pl)	2006-01-19	2007-01-19	Zastosowanie kombinacji morfiny i co najmniej jednego antagonisty opiatów do leczenia uzależnienia od opiatów i do zapobiegania niedoustnemu nadużywaniu opiatów przez uzależnionych od opiatów

Country Status (19)

Country	Link
US (2)	US20100221339A1 (pl)
EP (2)	EP1810678A1 (pl)
CN (2)	CN101370503A (pl)
AT (1)	ATE465735T1 (pl)
AU (1)	AU2007206914B2 (pl)
CA (1)	CA2637458C (pl)
CY (1)	CY1110152T1 (pl)
DE (1)	DE502007003589D1 (pl)
DK (1)	DK1976524T4 (pl)
EA (1)	EA014539B1 (pl)
ES (1)	ES2345286T5 (pl)
HK (1)	HK1198744A1 (pl)
HR (1)	HRP20100373T4 (pl)
PL (1)	PL1976524T5 (pl)
PT (1)	PT1976524E (pl)
RS (1)	RS51388B2 (pl)
SI (1)	SI1976524T1 (pl)
UA (1)	UA92380C2 (pl)
WO (1)	WO2007082935A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102007024428A1 (de)	2007-05-25	2008-11-27	Hermann, Holger Lars, Dr. med.	Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten
US20120040009A1 (en)	2009-04-22	2012-02-16	Lars Holger Hermann	Particulate pharmaceutical composition with an opioid and an opioid antagonist
JP2012087101A (ja)	2010-10-21	2012-05-10	Holger Hermann Lars	オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
WO2015089530A1 (de)	2013-12-20	2015-06-25	G.L. PHARMA GmbH	Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
EP3082816B1 (en)	2013-12-20	2019-03-20	Indivior UK Limited	Intranasal naloxone compositions and methods of making and using same
CN103695497B (zh) *	2013-12-20	2014-09-17	奇方(天津)医药科技有限公司	纳洛酮的酶法制备及其药物组合物
US20160256451A1 (en) *	2015-03-06	2016-09-08	Develco Pharma Schweiz Ag	Dosage of naloxone
WO2016193456A2 (en) *	2015-06-03	2016-12-08	Develco Pharma Schweiz Ag	Opioid receptor antagonist for use in treating patients with severe constipation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1390772A (en) *	1971-05-07	1975-04-16	Endo Lab	Oral narcotic composition
US4769372A (en) *	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580876A (en) †	1992-09-21	1996-12-03	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
SE9301057L (sv)	1993-03-30	1994-10-01	Pharmacia Ab	Beredning med kontrollerad frisättning
DE4325465B4 (de) *	1993-07-29	2004-03-04	Zenz, Michael, Prof. Dr.med.	Orales pharmazeutisches Präparat für die Schmerztherapie
AT403988B (de)	1994-05-18	1998-07-27	Lannacher Heilmittel	Festes orales retardpräparat
US5965161A (en)	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
PT914097E (pt) *	1996-03-12	2002-06-28	Alza Corp	Composicao e forma de dosagem compreendendo antagonista de opioide
DE59812355D1 (de)	1997-11-06	2005-01-13	Lannacher Heilmittel	Orale Retard-Präparation enthaltend Tramadol sowie Verfahren zu ihrer Herstellung
DK1685839T3 (da) *	1997-12-22	2013-06-24	Euro Celtique Sa	Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) *	1997-12-22	2005-06-08	欧罗赛铁克股份有限公司	防止阿片样物质滥用的方法
WO1999040898A2 (en)	1998-02-12	1999-08-19	Centrapharm Inc.	Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
AU776666B2 (en) *	2000-02-08	2004-09-16	Euro-Celtique S.A.	Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) †	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
US20030044458A1 (en) †	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
CA2478515C (en)	2002-04-05	2010-09-28	Purdue Pharma	Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en)	2002-09-20	2018-07-23	Alpharma Pharmaceuticals Llc	SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20050191244A1 (en) *	2002-10-25	2005-09-01	Gruenenthal Gmbh	Abuse-resistant pharmaceutical dosage form
US20040110781A1 (en) *	2002-12-05	2004-06-10	Harmon Troy M.	Pharmaceutical compositions containing indistinguishable drug components
AT503858B1 (de)	2003-06-05	2008-08-15	Lannacher Heilmittel	Verfahren zur herstellung einer festen oralen pharmazeutischen zusammensetzung, enthaltend ein jodsalz
WO2006079550A2 (en)	2005-01-28	2006-08-03	Euro-Celtique S.A.	Alcohol resistant dosage forms
EP1604666A1 (en)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
FR2889810A1 (fr) *	2005-05-24	2007-02-23	Flamel Technologies Sa	Forme medicamenteuse orale, microparticulaire, anti-mesurage
GB2438401A (en)	2006-05-25	2007-11-28	Alpharma Aps	Preparation of morphinan derivatives comprising N-demethylation, reductive amination and O-demethylation steps
KR101486228B1 (ko)	2006-06-19	2015-01-26	알파마 파머슈티컬스 엘엘씨	약제학적 조성물

2006
- 2006-01-19 EP EP06100578A patent/EP1810678A1/de not_active Withdrawn
2007
- 2007-01-19 US US12/161,397 patent/US20100221339A1/en not_active Abandoned
- 2007-01-19 UA UAA200810463A patent/UA92380C2/ru unknown
- 2007-01-19 RS RS20100341A patent/RS51388B2/sr unknown
- 2007-01-19 SI SI200730285T patent/SI1976524T1/sl unknown
- 2007-01-19 AU AU2007206914A patent/AU2007206914B2/en not_active Ceased
- 2007-01-19 CN CNA2007800026334A patent/CN101370503A/zh active Pending
- 2007-01-19 EP EP07704010.3A patent/EP1976524B2/de active Active
- 2007-01-19 ES ES07704010.3T patent/ES2345286T5/es active Active
- 2007-01-19 DE DE502007003589T patent/DE502007003589D1/de active Active
- 2007-01-19 PL PL07704010T patent/PL1976524T5/pl unknown
- 2007-01-19 DK DK07704010.3T patent/DK1976524T4/en active
- 2007-01-19 CN CN201410124301.5A patent/CN103893179A/zh active Pending
- 2007-01-19 AT AT07704010T patent/ATE465735T1/de active
- 2007-01-19 CA CA2637458A patent/CA2637458C/en active Active
- 2007-01-19 HR HRP20100373TT patent/HRP20100373T4/hr unknown
- 2007-01-19 PT PT07704010T patent/PT1976524E/pt unknown
- 2007-01-19 WO PCT/EP2007/050540 patent/WO2007082935A1/de not_active Ceased
- 2007-01-19 EA EA200870182A patent/EA014539B1/ru unknown
2010
- 2010-06-24 CY CY20101100578T patent/CY1110152T1/el unknown
2014
- 2014-12-04 HK HK14112247.0A patent/HK1198744A1/xx unknown
2016
- 2016-06-20 US US15/187,374 patent/US10507205B2/en active Active

Also Published As

Publication number	Publication date
WO2007082935A1 (de)	2007-07-26
EP1976524A1 (de)	2008-10-08
PL1976524T5 (pl)	2017-12-29
ES2345286T5 (es)	2017-04-25
CN101370503A (zh)	2009-02-18
RS51388B (sr)	2011-02-28
EP1810678A1 (de)	2007-07-25
DK1976524T4 (en)	2016-12-05
CY1110152T1 (el)	2015-01-14
HRP20100373T4 (hr)	2016-12-16
PT1976524E (pt)	2010-07-05
CA2637458C (en)	2015-03-10
UA92380C2 (ru)	2010-10-25
US10507205B2 (en)	2019-12-17
AU2007206914B2 (en)	2012-08-23
SI1976524T1 (sl)	2010-08-31
DK1976524T3 (da)	2010-08-09
HK1198744A1 (en)	2015-06-05
HRP20100373T1 (en)	2010-08-31
ATE465735T1 (de)	2010-05-15
CA2637458A1 (en)	2007-07-26
US20100221339A1 (en)	2010-09-02
ES2345286T3 (es)	2010-09-20
DE502007003589D1 (de)	2010-06-10
RS51388B2 (sr)	2018-02-28
EP1976524B2 (de)	2016-08-10
EP1976524B1 (de)	2010-04-28
CN103893179A (zh)	2014-07-02
EA014539B1 (ru)	2010-12-30
EA200870182A1 (ru)	2009-02-27
AU2007206914A1 (en)	2007-07-26
US20170136005A1 (en)	2017-05-18

Publication	Publication Date	Title
Reimer et al.	2008	Meeting the challenges of opioid-induced constipation in chronic pain management–a novel approach
PL1976524T5 (pl)	2017-12-29	Zastosowanie kombinacji morfiny i co najmniej jednego antagonisty opiatów do leczenia uzależnienia od opiatów i do zapobiegania niedoustnemu nadużywaniu opiatów przez uzależnionych od opiatów
Lugo et al.	2005	The pharmacokinetics of oxycodone
IL221795B (en)	2018-06-28	Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
TWI365880B (en)	2012-06-11	Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2008131056A3 (en)	2009-12-03	Sustained release monoeximic formulations of opioid and nonopioid analgesics
WO2008131057A3 (en)	2009-12-03	Sustained release formulations of opioid and nonopioid analgesics
EA200870449A1 (ru)	2009-04-28	Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
MY161079A (en)	2017-04-14	Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
US10660900B2 (en)	2020-05-26	Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
MX2009002196A (es)	2009-03-13	Oblea de buprenorfina para terapia de sustitucion de farmacos.
WO2005107726A3 (en)	2006-08-24	Method for the treatment of back pain
MX2009009131A (es)	2009-09-03	Mejoras en y con relacion a composiciones medicinales.
GB0315861D0 (en)	2003-08-13	Improvements in pharmaceutical compositions for treatment of drug abuse
SI1765349T1 (sl)	2011-04-29	Opioidi za zdravljenje kronične obstrukcijske pljučne bolezni (KOPB)
Campbell et al.	2006	Antinociceptive effects of alcohol and nicotine: involvement of the opioid system
UA109781C2 (uk)	2015-10-12	Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
IL179896A (en)	2013-07-31	Opioid with a delayed oral dosage form containing a mixture of opioid agonist and antagonist for use in the treatment of nervous leg syndrome
ZA200610770B (en)	2008-08-27	Dosage form for delivery of multiple drug forms
JP7244992B2 (ja)	2023-03-23	オピオイドとｎ－アシルエタノールアミンの組み合わせ
RU2012124063A (ru)	2013-12-20	Лекарственная комбинация с теобромином и ее использование в лечении
Kumar et al.	2010	L-type calcium channel blockers, morphine and pain: Newer insights
US20030199496A1 (en)	2003-10-23	Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
WO2006041769A3 (en)	2007-06-14	Methods for the treatment of substance abuse and addiction
Silverman	2015	Buprenorphine for pain and opioid dependence